TY - JOUR
T1 - Recent Advances of Nanocarriers for Effective Delivery of Therapeutic Peptides
AU - Atabakhshi-Kashi, Mona
AU - Geranpayehvaghei, Marzieh
AU - Wang, Yazhou
AU - Akhbariyoon, Hamidreza
AU - Taleb, Mohammad
AU - Zhang, Yinlong
AU - Khajeh, Khosro
AU - Nie, Guangjun
N1 - Funding Information:
To address unmet needs of medical treatment, the use of peptides as therapeutics has shown tremendous potential over other medications such as proteins, owing to their unique advantages, including high selectivity and biocompatibility. Furthermore, peptide drugs can endure harsh manufacturing conditions better than protein drugs. Nonetheless, due to the given intrinsic weaknesses, peptides are not directly suitable for use as available therapeutics. Suboptimal physicochemical and pharmacokinetic properties of peptide therapeutics can be tackled through taking advantage of nanocarrier-based platforms. Over the past decades, nanoparticles and colloidal systems have successfully been applied both in industry and medicine, and many designs and structures have been evaluated. As drug delivery vehicles, nanocarriers are intended to protect peptide payloads from premature degradation, enhance the controlled release of them in the target tissue, and improve their cellular uptake. Synergism between peptide drugs and nanoparticulate systems would make substantial progress toward the development of the next generation of personalized medicine and help to overcome insurmountable challenges in the clinical translations of therapeutic peptides. The rational design of peptide-carrying nanoparticles should undergo profound adjustments concerning sophisticated physicochemical features of biological systems and target tissues. Delivering pharmacologically active peptide to specific tissues or cells through their incorporation into nanocarriers encounters various challenges. Functional modifications to overcome their drawbacks are under investigation and include hybridization of two or more materials into the unified construction, as well as developing new formulations containing self-assembled peptide nanoparticulates or colloidal systems. Such strategies have the potential to develop advanced peptide-based therapeutics. The need for future research may be centered on the perfection of the safety and efficiency of nanoparticles for noninvasive administration and high patient compliance.nteIaion amrcong ditfferenteserch araeasruscamei-htr as als, chemistry, biology, and medicine will enable us to rationally engineer and provide the multifaceted tools to overcome the major challenges that prevent this technology from being translated to the clinic. Acknowledgments This work was supported by grants from the National Key R&D Program of China (2018YFA0208900). We also thank the research core of Tarbiat Modares University for the financial support withrgntaum benr IG-39707. Conflict of interest The authors declare there is no conflict of interest. For signed statements, please contact the journal office: [email protected] Quote this article as Atabakhshi-Kashi M, Geranpayehvaghei M, Wang Y, Akhbariyoon H, Taleb M, Zhang Y, Khajeh K, Nie G, Recent Advances of Nanocarriers for Effective Delivery of Therapeutic Peptides, Precis. Nanomed. 2020 July;3(3):549-576, https://doi.org/10.33218/001c.13444 References 1. Rastogi, S., Shukla, S., Kalaivani, M. & Singh, G. N. Peptide-based therapeutics: quality specifications, regulatoryoncseraitionds, andrpseocts. DprugiDosv. Todcay4,24 8–162 1(2019). 2. Schlueter, N. et al. Metabolic actions of natriuretic peptides and therapeutic potential in the metabolic syndrome. Pharmacol. Ther. 144, 12–27 (2014). 3. Xiao, Y.-F. et al. Peptide-Based Treatment: A Promising Cancer Therapy. J. Immunol. Res. 2015, 1–13 (2015). 4. Kotraiah, V. et al. Novel Peptide-Based PD1 Immunomodulators Demonstrate Efficacy in Infectious DiseaseacVcines andheTrpeuatics. Front. Immunol. 11, 1–17 (2020). 5. Usmani, S. S. et al. THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS One 12, 1–12 (2017). 6. Research, G. V. Peptide Therapeutics Market By Application (Cancer, Cardiovascular Disorder, Metabolic Disorder, Respiratory Disorder, Pain, Dermatology), By Type (Generic, Innovative) By Type of Manufacturers (In-house, Outsourced), And Segment Forecasts, 2018 - 2025. Peptide TherapeuticsMarketSize,Growth|GlobalIndustryepRort 20250(17).2 7. Market Research Report, PNS Pharma. Glob. Pept. Ther. Mark. Clin. Trials Insight 2026 (2020). 8. Lee, A. C. L., Harris, J. L., Khanna, K. K. & Hong, J. H. A comprehensive review on current advances in peptide drug development and design. Int. J. Mol. Sci. 20, 1–21 (2019).
Publisher Copyright:
© 2020 by Author(s)
PY - 2020
Y1 - 2020
N2 - Precisely selective interactions of peptides with their unique binding partners represent an outstanding starting point for designing novel therapeutics. It is well established that peptides with a variety of critical physiological functions and specific mechanisms of action offer distinct advantages, including excellent safety and higher efficiency over traditional small molecule therapeutics. Certain intrinsic weaknesses of naturally occurring peptides such as negligible plasma half-life, low bioavailability, and potential immunogenicity have limited their administration as medicines. Nanotechnology has expanded several promising strategies to address the limitations associated with therapeutic peptides. This review aims to perform a state-of-the-art summary of the strategies that are actively used to develop efficient formulations of nanosystem based peptide medicines. We first focus on the recent advances and updates on peptide-based nanomedicines. Then we indicate how nanosystems improved the functionality of therapeutic peptides and what the future opportunities and challenges of developments in the field of therapeutic peptides are. Potential noninvasive delivery platforms for peptide incorporated nanoparticles through alternative administration routes are also discussed.
AB - Precisely selective interactions of peptides with their unique binding partners represent an outstanding starting point for designing novel therapeutics. It is well established that peptides with a variety of critical physiological functions and specific mechanisms of action offer distinct advantages, including excellent safety and higher efficiency over traditional small molecule therapeutics. Certain intrinsic weaknesses of naturally occurring peptides such as negligible plasma half-life, low bioavailability, and potential immunogenicity have limited their administration as medicines. Nanotechnology has expanded several promising strategies to address the limitations associated with therapeutic peptides. This review aims to perform a state-of-the-art summary of the strategies that are actively used to develop efficient formulations of nanosystem based peptide medicines. We first focus on the recent advances and updates on peptide-based nanomedicines. Then we indicate how nanosystems improved the functionality of therapeutic peptides and what the future opportunities and challenges of developments in the field of therapeutic peptides are. Potential noninvasive delivery platforms for peptide incorporated nanoparticles through alternative administration routes are also discussed.
KW - Therapeutic peptides
KW - nanoparticles
KW - noninvasive administration
KW - peptide delivery
KW - peptide encapsulation
UR - http://www.scopus.com/inward/record.url?scp=85106259654&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106259654&partnerID=8YFLogxK
U2 - 10.33218/001c.13444
DO - 10.33218/001c.13444
M3 - Review article
AN - SCOPUS:85106259654
SN - 2639-9431
VL - 3
SP - 549
EP - 576
JO - Precision Nanomedicine
JF - Precision Nanomedicine
IS - 2
ER -